Regulatory Role of MSMB in Lymphoma and Its Tumor Suppressor Function Across Cancer Types 2258421

Abstract

Abstract Introduction Lymphoma is a globally prevalent malignancy driven by diverse genetic alterations. Identifying novel genes that influence tumor growth provides critical insight into mechanisms of oncogenesis. The gene MSMB (β-microseminoprotein), a known tumor suppressor in prostate cancer, may have a broader regulatory role in other cancers. This study investigates whether MSMB functions similarly as a tumor suppressor in lymphoma, linking computational predictions with functional validation. Methods RNA-seq data (project PRJNA314605) were analyzed to identify genes differentially expressed in lymphoma. MSMB was found to be strongly downregulated (log₂ fold change ≈ —19.6). To evaluate its functional role, CRISPR-Cas9 knockout was performed in lymphoma cell lines expressing normal MSMB levels. Cell viability was measured using the Trypan Blue exclusion assay and compared to unmodified control cells. Results Computational analysis confirmed significant MSMB downregulation in lymphoma compared with normal tissue. Knockout of MSMB resulted in increased viable cell counts relative to controls, suggesting that loss of MSMB promotes proliferation. These findings parallel the gene’s established tumor-suppressive role in prostate cancer, supporting shared molecular mechanisms across tumor types. Conclusion MSMB appears to act as a tumor suppressor in both prostate cancer and lymphoma. Its downregulation and the enhanced cell viability following knockout support a conserved role in limiting tumor growth. Further mechanistic studies will clarify how MSMB regulates proliferation and assess its potential as a therapeutic target in diverse cancers. Funding Source n/a Topic Categories Translational and Interventional Immunology (TI)